Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd Valuation

Q: What is the Fair Price of 1349 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

1349 (HK$2.23) is trading below our estimate of [[fair value]] (HK$5.56)

Is 1349 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1349 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 1349 (HK$2.23) is trading below our estimate of fair value (HK$5.56)

Significantly Below Fair Value: 1349 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1349?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for 1349. This is calculated by dividing 1349's market cap by their current preferred multiple.
What is 1349's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	CN¥6.40b

1349 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	6.4x
Enterprise Value/EBITDA	54.9x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does 1349's PE Ratio compare to its peers?

The above table shows the PE ratio for 1349 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	13.3x
1666 Tong Ren Tang Technologies	11.2x	4.5%	HK$7.2b
3613 Beijing Tong Ren Tang Chinese Medicine	15.4x	15.2%	HK$8.3b
2877 China Shineway Pharmaceutical Group	6.7x	14.5%	HK$7.1b
2186 Luye Pharma Group	19.9x	26.8%	HK$11.5b
1349 Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd	20.9x	n/a	HK$6.9b

Price-To-Earnings vs Peers: 1349 is expensive based on its Price-To-Earnings Ratio (20.9x) compared to the peer average (13.3x).

Price to Earnings Ratio vs Industry

How does 1349's PE Ratio compare vs other companies in the HK Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	12.5%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	12.5%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: 1349 is expensive based on its Price-To-Earnings Ratio (20.9x) compared to the Hong Kong Pharmaceuticals industry average (8.3x).

Price to Earnings Ratio vs Fair Ratio

What is 1349's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1349 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	20.9x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 1349's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.